Kura Oncology develops targeted cancer medicines, including KOMZIFTI, an oral treatment for a form of acute myeloid leukemia. It last closed at $7.49 on Nov 17, up 5.64% on the day. KURA last reported earnings on Tue, Nov 10, 2026.
Only 1 firm rated KURA in the past 90 days, not enough for a consensus
Average 12-month target
$30.00
▲ 300.5% upside
Based on 1 analyst who set a price target on KURA in the past 90 days. The average target is $30.00, with a high of $30.00 and a low of $30.00, compared with the last close of $7.49.
Highest target$30.00
Average target$30.00
Lowest target$30.00
Latest rating changes
JP MorganInitiated
Oct 1Buy$30
WedbushTarget raised
Aug 13Buy$36 → $38
WedbushReiterated
Jul 28Buy$36
CitizensReiterated
Jun 15Buy$24
Lake StreetInitiated
Apr 14Buy$23
Date
Firm
Action
Rating
Price target
Oct 1
JP Morgan
Initiated
Buy
$30
Aug 13
Wedbush
Target raised
Buy
$36 → $38
Jul 28
Wedbush
Reiterated
Buy
$36
Jun 15
Citizens
Reiterated
Buy
$24
Apr 14
Lake Street
Initiated
Buy
$23
Loading…
Technical Analysis
KURA · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 16% below its 20 day and 33% below its 50 day average. It is 30% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 37), near oversold. The nearest support is the Pivot S1 at $7.23, and the nearest resistance the Pivot R1 at $7.75.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.0%/day
Key levels
$13.9052 week high+85.6%
$10.54100 day average+40.7%
$9.9550 day average+32.8%
$9.77200 day average+30.4%
$8.7220 day average+16.4%
$8.25Swing high (Nov 11)+10.1%
$7.75Pivot R1+3.5%
$7.49Pivot+0.0%
$7.49Last close
$7.23Pivot S1−3.5%
$6.7552 week low−9.9%
$6.75Swing low (Nov 6)−9.9%
Indicators
RSI (14)
37.42
Weak, oversold below 30
Neutral
MACD
-0.80
Below its signal line
Bearish
Stochastic
16.6
Near the bottom of its range
Oversold
ADX (14)
28.6
Trending down
Williams %R
-82.4
Oversold below −80, overbought above −20
Oversold
CCI (20)
-70.3
Oversold below −100, overbought above 100
Neutral
Rate of change
−24.2%
Change over 10 sessions
Bearish
ATR (14)
$0.67
Typical daily range, 9.0% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Falling, nearing oversold
Short trendBearish
Long trendNot enough history
MomentumWeak
StretchNear oversold
VolatilityHigh, 18.8%/day
Key levels
$13.9052 week high+85.6%
$10.54100 day average+40.7%
$9.9550 day average+32.8%
$9.77200 day average+30.4%
$8.7220 day average+16.4%
$8.25Swing high (Nov 11)+10.1%
$7.75Pivot R1+3.5%
$7.49Pivot+0.0%
$7.49Last close
$7.23Pivot S1−3.5%
$6.7552 week low−9.9%
$6.75Swing low (Nov 6)−9.9%
Indicators
RSI (14)
39.18
Weak, oversold below 30
Neutral
MACD
-0.46
Below its signal line
Bearish
Stochastic
10.6
Near the bottom of its range
Oversold
ADX (14)
18.3
No clear trend
Williams %R
-89.7
Oversold below −80, overbought above −20
Oversold
CCI (20)
-168.3
Oversold below −100, overbought above 100
Oversold
Rate of change
−34.2%
Change over 10 sessions
Bearish
ATR (14)
$1.41
Typical daily range, 18.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200–
What happened before, for KURA
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how KURA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow KURA usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How KURA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2015.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KURA is in one of them and how their past KURA trades turned out.
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About Kura Oncology
Kura Oncology is a biopharmaceutical company based in San Diego, California, that develops targeted medicines for cancer and blood diseases. Its first approved product, KOMZIFTI, is taken by mouth to treat adults with relapsed or refractory acute myeloid leukemia who carry a susceptible NPM1 mutation. The company is also studying its drug candidates in solid tumors, including kidney, lung, colorectal and pancreatic cancers, often alongside standard treatments.